These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 16364487)

  • 1. Hepatotoxicity of antiretrovirals: incidence, mechanisms and management.
    Núñez M
    J Hepatol; 2006; 44(1 Suppl):S132-9. PubMed ID: 16364487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatotoxicity of antiretrovirals: incidence, mechanisms and management.
    Núñez M; Soriano V
    Drug Saf; 2005; 28(1):53-66. PubMed ID: 15649105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HAART and liver: is it safe?
    Antonello VS; Kliemann DA; Rigel Santos B; Tovo CV
    J Infect Dev Ctries; 2014 Nov; 8(11):1444-50. PubMed ID: 25390056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Steatohepatitis due to antiretroviral therapy.
    Gayle F; Lee MG; Hanchard B; Mills M
    West Indian Med J; 2008 Jan; 57(1):66-9. PubMed ID: 19565942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatotoxicity of antiretroviral drugs in HIV HCV patients with congenital coagulopathies followed at an Haemophilia Unit during a decade.
    Sauleda S; Martorell M; Esteban JI; Tural C; Ruiz I; Puig L; Esteban R; Guardia J; Vargas V
    Haemophilia; 2006 May; 12(3):228-36. PubMed ID: 16643206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients.
    Labarga P; Soriano V; Vispo ME; Pinilla J; Martin-Carbonero L; Castellares C; Casado R; Maida I; Garcia-Gasco P; Barreiro P
    J Infect Dis; 2007 Sep; 196(5):670-6. PubMed ID: 17674307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort.
    Torti C; Lapadula G; Casari S; Puoti M; Nelson M; Quiros-Roldan E; Bella D; Pastore G; Ladisa N; Minoli L; Sotgiu G; Mazzotta F; Lo Caputo S; Di Perri G; Filice G; Tinelli C; Carosi G;
    BMC Infect Dis; 2005 Jul; 5():58. PubMed ID: 16018804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical syndromes and consequences of antiretroviral-related hepatotoxicity.
    Núñez M
    Hepatology; 2010 Sep; 52(3):1143-55. PubMed ID: 20812358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective, open-label comparative study of liver toxicity in an unselected population of HIV-infected patients treated for the first time with efavirenz or nevirapine.
    Manfredi R; Calza L; Chiodo F
    HIV Clin Trials; 2005; 6(6):302-11. PubMed ID: 16452064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patient/physician choice in patients with hepatitis C coinfection.
    Mocroft A; Phillips AN; Soriano V; Rockstroh J; Blaxhult A; Katlama C; Boron-Kaczmarska A; Viksna L; Kirk O; Lundgren JD;
    AIDS Res Hum Retroviruses; 2005 Jun; 21(6):527-36. PubMed ID: 15989457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiretroviral drugs and liver injury.
    Soriano V; Puoti M; Garcia-Gascó P; Rockstroh JK; Benhamou Y; Barreiro P; McGovern B
    AIDS; 2008 Jan; 22(1):1-13. PubMed ID: 18090386
    [No Abstract]   [Full Text] [Related]  

  • 12. Acute liver enzyme elevations in HIV-1-infected patients.
    Livry C; Binquet C; Sgro C; Froidure M; Duong M; Buisson M; Grappin M; Quantin C; Portier H; Chavanet P; Piroth L
    HIV Clin Trials; 2003; 4(6):400-10. PubMed ID: 14628283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Highly active antiretroviral therapy-induced liver injury.
    Inductivo-Yu I; Bonacini M
    Curr Drug Saf; 2008 Jan; 3(1):4-13. PubMed ID: 18690975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatotoxicity of antiretroviral therapy.
    Kontorinis N; Dieterich D
    AIDS Rev; 2003; 5(1):36-43. PubMed ID: 12875106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV infection and hepatic enzyme abnormalities: intricacies of the pathogenic mechanisms.
    Pol S; Lebray P; Vallet-Pichard A
    Clin Infect Dis; 2004 Mar; 38 Suppl 2():S65-72. PubMed ID: 14986277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patient/physician choice in patients with hepatitis C coinfection.
    Mocroft A; Phillips AN; Soriano V; Rockstroh J; Blaxhult A; Katlama C; Boron-Kaczmarska A; Viksna L; Kirk O; Lundgren JD;
    AIDS Res Hum Retroviruses; 2005 Sep; 21(9):743-52. PubMed ID: 16218797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection.
    Aranzabal L; Casado JL; Moya J; Quereda C; Diz S; Moreno A; Moreno L; Antela A; Perez-Elias MJ; Dronda F; Marín A; Hernandez-Ranz F; Moreno A; Moreno S
    Clin Infect Dis; 2005 Feb; 40(4):588-93. PubMed ID: 15712082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy.
    Wit FW; Weverling GJ; Weel J; Jurriaans S; Lange JM
    J Infect Dis; 2002 Jul; 186(1):23-31. PubMed ID: 12089658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV treatment-associated hepatitis.
    Orenstein R; LeGall-Salmon E
    AIDS Read; 1999 Aug; 9(5):339-46. PubMed ID: 12737123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Period of onset and lack of clinical manifestation of hepatotoxicity after commencing highly active antiretroviral therapy.
    Ugiagbe RA; Ugiagbe EE
    Niger J Clin Pract; 2012; 15(1):63-7. PubMed ID: 22437093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.